Abstract
Novel bisarylcarboxylic acids, both [2-(2-benzyloxyphenyl)-cyclopent-1-enyl]-benzoic acids and heteoarylcarboxylic acid analogues, with EP1 receptor antagonist activity are claimed. The claimed compounds define a novel scaffold for such activity and are claimed to be useful in the treatment of pain and other disorders.